Cargando…
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
Strategies boosting both innate and adaptive immunity have great application prospects in cancer immunotherapy. Antibodies dual blocking the innate checkpoint CD47 and adaptive checkpoint PD-L1 or TIGIT could achieve durable anti-tumor effects. However, a small molecule dual blockade of CD47/SIRPα a...
Autores principales: | Zhou, Xiuman, Jiao, Ling, Qian, Yuzhen, Dong, Qingyu, Sun, Yixuan, Zheng, Wei V., Zhao, Wenshan, Zhai, Wenjie, Qiu, Lu, Wu, Yahong, Wang, Hongfei, Gao, Yanfeng, Chen, Junhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150775/ https://www.ncbi.nlm.nih.gov/pubmed/34068552 http://dx.doi.org/10.3390/biom11050706 |
Ejemplares similares
-
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020) -
Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021) -
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020) -
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020) -
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
por: Diong, SJ J., et al.
Publicado: (2023)